Weiss Multi-Strategy Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,987	Closed	-$1.8M	–	629
2023 Q1	$1.8M	Sell	8,987 -2,708	-23%	-$569K	0.04%	436
2022 Q4	$2.78M	Buy	11,695 +3,734	+47%	+$796K	0.08%	331
2022 Q3	$1.59M	Buy	7,961 +5,551	+230%	+$1.06M	0.04%	441
2022 Q2	$351K	Buy	+2,410	New	+$342K	0.01%	575
2016 Q3	–	Sell	-3,645	Closed	-$202K	–	415
2016 Q2	$202K	Sell	3,645 -4,355	-54%	-$274K	0.02%	374
2016 Q1	$502K	Sell	8,000 -1,000	-11%	-$66.5K	0.02%	387
2015 Q4	$847K	Sell	9,000 -126	-1%	-$11.7K	0.06%	258
2015 Q3	$733K	Buy	+9,126	New	+$1.01M	0.03%	288
2015 Q1	–	Sell	-11,000	Closed	-$1.07M	–	434
2014 Q4	$1.07M	Sell	11,000 -3,000	-21%	-$278K	0.04%	279
2014 Q3	$1.09M	Hold	14,000	–	–	0.03%	367
2014 Q2	$884K	Buy	14,000 +570	+4%	+$33.9K	0.02%	435
2014 Q1	$902K	Buy	+13,430	New	+$1.04M	0.02%	509

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ALNY Position: Q2 2023 in Review

Weiss Multi-Strategy Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 8,987 shares — an estimated $1.8M sold.

Weiss Multi-Strategy Advisers first reported a position in ALNY in Q1 2014 and held it in 12 quarters. The position peaked at $2.78M in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Weiss Multi-Strategy Advisers reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 8,987 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $1.8M.
Weiss Multi-Strategy Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Weiss Multi-Strategy Advisers's Alnylam Pharmaceuticals position peaked at $2.78M in Q4 2022.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.